{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:02:56Z","timestamp":1756339376972,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00374-x","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:44Z","timestamp":1756282244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review"],"prefix":"10.1186","volume":"11","author":[{"given":"Vanessa M.","family":"Barrionuevo-Villacis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio X.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"374_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140:971\u20139. https:\/\/doi.org\/10.1182\/blood.2020008377.","journal-title":"Blood"},{"key":"374_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/ijo.2021.5180","volume":"58","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yao Q, Zhang F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population. Int J Oncol. 2021;58:371\u201387. https:\/\/doi.org\/10.3892\/ijo.2021.5180.","journal-title":"Int J Oncol"},{"key":"374_CR3","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"key":"374_CR4","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00415-023-12143-w","volume":"271","author":"ME de Koning","year":"2024","unstructured":"de Koning ME, Hof JJ, Jansen C, et al. Primary central nervous system lymphoma. J Neurol. 2024;271:2906\u201313. https:\/\/doi.org\/10.1007\/s00415-023-12143-w.","journal-title":"J Neurol"},{"key":"374_CR5","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/ijms21103483","volume":"21","author":"P Ko\u017ami\u0144ski","year":"2020","unstructured":"Ko\u017ami\u0144ski P, Halik PK, Chesori R, Gniazdowska E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020;21:3483. https:\/\/doi.org\/10.3390\/ijms21103483. (antes 4).","journal-title":"Int J Mol Sci"},{"issue":"1","key":"374_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1188\/23.CJON.47-54","volume":"27","author":"B Roche","year":"2023","unstructured":"Roche B, Clarke PA, Ford D, Collins Shaver S, Thompson J. High-dose methotrexate: nursing considerations for administration and supportive care. Clin J Oncol Nurs. 2023;27(1):47\u201354. https:\/\/doi.org\/10.1188\/23.CJON.47-54.","journal-title":"Clin J Oncol Nurs"},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/17425255.2023.2272593","volume":"19","author":"K Kielbowski","year":"2023","unstructured":"Kielbowski K, Rosik J, Bakinowska E, et al. The use of glucarpidase as a rescue therapy for high-dose methotrexate toxicity: a review of Pharmacological and clinical data. Expert Opin Drug Metab Toxicol. 2023;19:741\u201350. https:\/\/doi.org\/10.1080\/17425255.2023.2272593.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41598-020-80724-0","volume":"11","author":"J Yu","year":"2021","unstructured":"Yu J, Du H, Ye X, Zhang L, Xiao H. High-dose methotrexate-based regimens and post remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Sci Rep. 2021;11:2125. https:\/\/doi.org\/10.1038\/s41598-020-80724-0.","journal-title":"Sci Rep"},{"key":"374_CR9","unstructured":"DailyMed. RITUXIMAB- rituximab injection [Internet]. U.S. National Library of Medicine; [cited 2025 Jul 8]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563"},{"key":"374_CR10","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/leu.2017.170","volume":"31","author":"B Kasenda","year":"2017","unstructured":"Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous Haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German cooperative PCNSL study group. Leukemia. 2017;31:2623\u20139. https:\/\/doi.org\/10.1038\/leu.2017.170.","journal-title":"Leukemia"},{"key":"374_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","volume":"133","author":"C Houillier","year":"2017","unstructured":"Houillier C, Ghesqui\u00e8res H, Chabrot C, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma in elderly individuals: a LOC network study. J Neurooncol. 2017;133:315\u201320. https:\/\/doi.org\/10.1007\/s11060-017-2435-7.","journal-title":"J Neurooncol"},{"issue":"8","key":"374_CR12","doi-asserted-by":"publisher","first-page":"e1273","DOI":"10.1634\/theoncologist.2020-0489","volume":"26","author":"MM Herr","year":"2021","unstructured":"Herr MM, Barnholtz-Sloan JS, Bokstein F, et al. Treatment options for relapsed and refractory primary CNS lymphoma: the international primary CNS lymphoma collaborative group (IPCG) consensus. Oncologist. 2021;26(8):e1273\u201382. https:\/\/doi.org\/10.1634\/theoncologist.2020-0489.","journal-title":"Oncologist"},{"issue":"1","key":"374_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10637-017-0485-5","volume":"36","author":"T Oyakawa","year":"2018","unstructured":"Oyakawa T, Iida K, Kusuhara M, Kenmotsu H, Sugino T. Chemotherapy-induced cardiomyopathy caused by pemetrexed. Invest New Drugs. 2018;36(1):147\u201350. https:\/\/doi.org\/10.1007\/s10637-017-0485-5.","journal-title":"Invest New Drugs"},{"key":"374_CR14","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(20)30031-4","volume":"7","author":"M Linschoten","year":"2020","unstructured":"Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7:e295\u2013308. https:\/\/doi.org\/10.1016\/S2352-3026(20)30031-4.","journal-title":"Lancet Haematol"},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neurol.2023.03.012","volume":"179","author":"A Rachdi","year":"2023","unstructured":"Rachdi A, Hernandez-Tost H, Herzi D, et al. Recent advances in the diagnosis and the treatment of primary CNS lymphoma. Rev Neurol (Paris). 2023;179:481\u20139. https:\/\/doi.org\/10.1016\/j.neurol.2023.03.012.","journal-title":"Rev Neurol (Paris)"},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","volume":"18","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Mrugala MM, Grommes C, et al. Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Canc Netw. 2020;18:1571\u20138. https:\/\/doi.org\/10.6004\/jnccn.2020.7667.","journal-title":"J Natl Compr Canc Netw"},{"key":"374_CR17","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.3390\/cancers13215372","volume":"13","author":"LR Schaff","year":"2021","unstructured":"Schaff LR, Grommes C. Update on novel therapeutics for primary CNS lymphoma. Cancers (Basel). 2021;13:5372. https:\/\/doi.org\/10.3390\/cancers13215372.","journal-title":"Cancers (Basel)"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Ali HJ, Koutroumpakis E, Ganatra S, Deswal A. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024;385:e075859. https:\/\/doi.org\/10.1136\/bmj-2023-075859.","journal-title":"BMJ"},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.34787","volume":"129","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Jones JE, George B, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023;129:2192\u2013200. https:\/\/doi.org\/10.1002\/cncr.34787.","journal-title":"Cancer"},{"issue":"41","key":"374_CR20","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC\/ICOS guidelines on cardio-oncology developed in collaboration with the European hematology association, the European society for therapeutic radiology and oncology, and the international Cardio-Oncology society. Eur Heart J. 2022;43(41):4229\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"2","key":"374_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE, et al. Cardio-oncology and heart failure: a scientific statement from the heart failure society of America. J Card Fail. 2025;31(2):415\u201355. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045.","journal-title":"J Card Fail"},{"key":"374_CR22","doi-asserted-by":"publisher","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","volume":"151","author":"X Li","year":"2020","unstructured":"Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151:104577. https:\/\/doi.org\/10.1016\/j.phrs.2019.104577.","journal-title":"Pharmacol Res"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00374-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:46Z","timestamp":1756282246000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00374-x","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}